A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
To evaluate the efficacy and safety of SHR-A2102 for injection versus Investigator-selected Therapy in patients with Locally advanced or Metastatic Urothelial Carcinoma who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.
Advanced Urothelial Carcinoma
DRUG: SHR-A2102 for Injection|DRUG: Docetaxel Injection|DRUG: Paclitaxel Injection|DRUG: Gemcitabine Hydrochloride for Injection|DRUG: Pemetrexed Disodium for Injection
Progression-free Survival (PFS), Up to approximately 1.5 years.|Overall Survival (OS), Up to approximately 1.5 years and 2 years.
Objective Response Rate (ORR), Up to approximately 1.5 years and 2 years.|Disease Control Rate (DCR), Up to approximately 1.5 years and 2 years.|Duration of Response (DoR), Up to approximately 1.5 years and 2 years.|Serum concentrations of SHR-A2102, Up to approximately 2 years.|Serum concentrations of SHR-A2102 toxin, Up to approximately 2 years.|Anti-SHR-A2102 antibody (ADA), Up to approximately 2 years.|Anti-SHR-A2102 neutralizing antibody (NAb), Up to approximately 2 years.|Incidence and severity of adverse event (AE), Up to approximately 2 years.|Incidence and severity of serious adverse event (SAE), Up to approximately 2 years.
To evaluate the efficacy and safety of SHR-A2102 for injection versus Investigator-selected Therapy in patients with Locally advanced or Metastatic Urothelial Carcinoma who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.